Bayer pharma chief sees no big acquisitions in near future
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
Bayer’s Head of Pharma Oelrich Expects Business to Return to Growth in 2027
Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
FiercePharma4d
JPM25: Bayer gears up for 'must-win battles' as Xarelto's decline is in full swing, pharma chief says
These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
Bayer to Scale Back Health Dealmaking Amid Push to Pay Down Debt
Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...
Bayer sees new drugs boosting return to growth in 2027, WSJ reports
Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...
MyNorthwest.com5d
Jury finds chemical company liable for $100M to individuals with illnesses linked to Monroe school
Pharmaceutic, chemical company Monsanto was found liable by a Washington jury for $100 million on Tuesday, according to ...
FierceBiotech6d
JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more
It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...
pharmaphorum1d
Bayer applies artificial intelligence to its pharmacovigilance systems
Bayer is looking to accelerate its patient safety data monitoring by using artificial intelligence in a move it hopes will allow any potential drug-related side effects to be detected much earlier.
Reuters6d
Bayer AG
A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals known as PCBs at a Seattle-area school, but found the company was not ...